Latest News and Press Releases
Want to stay updated on the latest news?
-
First Patient Dosed in Phase 2 Study of PARP/Tankyrase Inhibitor 2X-121 for Metastatic Breast Cancer
CAMBRIDGE, Mass. and HOERSHOLM, Denmark, June 26, 2018 (GLOBE NEWSWIRE) -- Oncology Venture US Inc., Oncology Venture AB (OV:ST) (“OV”) and Medical Prognosis Institute A/S...
-
HOERSHOLM, Denmark and CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Oncology Venture AB (OV:ST) (“OV” or the “Company”) announced today that three abstracts detailing clinical trials of its...
-
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in...
-
CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in...
-
HOERSHOLM, Denmark and CAMBRIDGE, Mass., July 07, 2017 (GLOBE NEWSWIRE) -- Oncology Venture AB (“Oncology Venture”) and 2X Oncology, Inc. ("2X Oncology"), today announced that Oncology Venture has...
-
CAMBRIDGE, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in...
-
CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a company focused on developing targeted therapeutics to address significant unmet needs in women’s...
-
CAMBRIDGE, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a company focused on developing targeted therapeutics to address significant unmet needs in women’s...